Zobrazeno 1 - 10
of 557
pro vyhledávání: '"yi ba"'
Autor:
Zhengyang Zhou, Hongdian Zhang, Jian Du, Jiayu Yang, Wen Pan, Qiumo Zhang, Huiya Wang, Peng Tang, Yi Ba, Haiyang Zhang
Publikováno v:
Cell Death and Disease, Vol 15, Iss 9, Pp 1-19 (2024)
Abstract The average five-year survival rate for esophageal cancer, a common malignant tumor of the digestive system, is barely 20%. The majority of esophageal squamous cell carcinoma (ESCC) patients had already progressed to a locally advanced or ev
Externí odkaz:
https://doaj.org/article/bd4222eef12c44c58bccd66fdd953704
Autor:
Ming Bai, Yao Lu, Chunmei Shi, Jianwei Yang, Wei Li, Xianli Yin, Chenghui Huang, Lin Shen, Liangzhi Xie, Yi Ba
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 7, Pp 636-650 (2024)
Objective: This study evaluated the safety and efficacy of an anti-epidermal growth factor receptor (EGFR) antibody (SCT200) and an anti-programmed cell death 1 (PD-1) antibody (SCT-I10A) as third-line or subsequent therapies in patients with rat sar
Externí odkaz:
https://doaj.org/article/94a160b89a9542698239a5646c220560
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Physical exercise intervention can significantly improve the liver of patients with Non-alcoholic fatty liver disease (NAFLD), but it is unknown which exercise mode has the best effect on liver improvement in NAFLD patients. Therefore, we sy
Externí odkaz:
https://doaj.org/article/3f4907efab374d5c83ed25e21a4fa0a8
Autor:
Jingjing Duan, Lila Zhu, Yinghui Shi, Weixue Wang, Tongtong Wang, Tao Ning, Le Zhang, Ming Bai, Hongli Li, Rui Liu, Shaohua Ge, Xia Wang, Yuchong Yang, Zhi Ji, Feixue Wang, Yansha Sun, Yi Ba, Ting Deng
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background There are various recommendations for third-line treatment in mCRC, however, there is no consensus on who is more suitable for particular strategy. Chemotherapy re-use in third-line setting is a common option in clinical practice.
Externí odkaz:
https://doaj.org/article/a26596c14aa84753aa2edb267d7deebc
Autor:
Feixue Wang, Yi Ba
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 12, Pp 934-941 (2023)
Externí odkaz:
https://doaj.org/article/257849a752b640aa8c17caa6f612fc41
Publikováno v:
MedComm, Vol 5, Iss 4, Pp n/a-n/a (2024)
Abstract Gastric cancer (GC) is among the most lethal human malignancies, yet it remains hampered by challenges in fronter of molecular‐guided targeted therapy to direct clinical treatment strategies. The protein tyrosine phosphatase Src homology 2
Externí odkaz:
https://doaj.org/article/e64752af679849669e3a28a2d3af4c56
Autor:
Lin Yang, Wen Zhang, Nanfeng Fan, Peiguo Cao, Ying Cheng, Lingjun Zhu, Suxia Luo, Hong Zong, Yuxian Bai, Jianfeng Zhou, Yanhong Deng, Yi Ba, Tianshu Liu, Mayinuer Aili, Xianli Yin, Kangsheng Gu, Guanghai Dai, Jieer Ying, Jianhua Shi, Yajie Gao, Wei Li, Guohua Yu, Liangzhi Xie, Wenlin Gai, Yan Wang, Peng Meng, Yuankai Shi
Publikováno v:
EBioMedicine, Vol 100, Iss , Pp 104966- (2024)
Summary: Background: Limited therapeutic options are available for metastatic colorectal cancer (mCRC) patients after failure of first- and second-line therapies, representing an unmet medical need for novel therapies. Methods: This is an open-label,
Externí odkaz:
https://doaj.org/article/51a30c01a2774b8782efcb9593d768c2
Autor:
Yuchong Yang, Yao Lu, Hui Tan, Ming Bai, Xia Wang, Shaohua Ge, Tao Ning, Le Zhang, Jingjing Duan, Yansha Sun, Rui Liu, Hongli Li, Yi Ba, Ting Deng
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Postoperative adjuvant chemotherapy (AC) is now well-accepted as standard for high-risk stage II and stage III colorectal cancer (CRC) patients, however the optimal time to initiate AC remains elusive. Methods A comprehensive lite
Externí odkaz:
https://doaj.org/article/cab21a1da0fb4981b7f40882e17f93c4
Autor:
Yuanyuan Zhao, Yuxiang Ma, Aimin Zang, Ying Cheng, Yiping Zhang, Xiangcai Wang, Zhendong Chen, Song Qu, Jianbo He, Chuanben Chen, Chuan Jin, Dongyuan Zhu, Qingshan Li, Xianling Liu, Wuyun Su, Yi Ba, Yanrong Hao, Junmin Chen, Guoping Zhang, Shenhong Qu, Yong Li, Weineng Feng, Mengxiang Yang, Baorui Liu, Weiwei Ouyang, Jin Liang, Zhuang Yu, Xiaoyan Kang, Shilin Xue, Guihong Yang, Wei Yan, Yingying Yang, Zhi Liu, Yufeng Peng, Bill Fanslow, Xian Huang, Li Zhang, Hongyun Zhao
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-16 (2023)
Abstract Background QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-life (t1/2) for CTLA-4
Externí odkaz:
https://doaj.org/article/544f44250125426d9ff048608c45236f
Autor:
Jin Li, Shukui Qin, Lu Wen, Junsheng Wang, Wenying Deng, Weijian Guo, Tongfu Jia, Da Jiang, Guifang Zhang, Yifu He, Yi Ba, Haijun Zhong, Lin Wang, Xiaoyan Lin, Jianwei Yang, Jun Zhao, Yuxian Bai, Xiangyuan Wu, Feng Gao, Guogui Sun, Yongjuan Wu, Feng Ye, Qiong Wang, Zhong Xie, Tienan Yi, Yong Huang, Guohua Yu, Lin Lu, Ying Yuan, Wei Li, Likun Liu, Yuping Sun, Ying Sun, Lifeng Yin, Zhiguo Hou
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background Apatinib, a highly selective VEGFR2 inhibitor, significantly improved efficacy versus placebo as a third- and later-line treatment for advanced gastric cancer in phase 2 and 3 trials. This prospective, single-arm, multicenter phas
Externí odkaz:
https://doaj.org/article/8f346a3b7ad5448abb9d1f638b99755a